RÉSUMÉ
Inflammatory conditions increase cardiovascular (CV) risk. Some nonsteroidal anti-inflammatory drugs (NSAIDs) that are used to treat pain and inflammation are also associated with CV complications. Inflammation, but not NSAIDs, disrupts the balance of vasodilator and vasoconstrictor components of the renin-angiotensin system within the heart. Herein, we report the effect of both inflammation and NSAIDs (rofecoxib, celecoxib, and meloxicam) on the physiologically active cytochrome P450 metabolites of arachidonic acid (ArA) in the rat with adjuvant arthritis. After oral administration of 7 daily therapeutically equivalent doses of NSAIDs or vehicle, the anti-inflammatory response, as well as the ArA metabolites and drug concentrations in plasma, heart and kidneys were assessed. Inflammation in the form of adjuvant arthritis caused a significant tissue-dependent imbalance of ArA metabolites by elevating the ratio of cardiotoxic 20-hydroxyeicosatetraenoic acid over cardioprotective epoxyeicosatrienoic acids in the heart, and reducing the ratio in the kidney. The observed imbalance was augmented by cardiotoxic rofecoxib but not by other examined NSAIDs with known milder cardiotoxicity. The cardio-renal toxicity of NSAIDs with known severe CV side effects may be due to altered cytochrome P450-mediated ArA acid metabolism. The ArA metabolism profile may be a marker of NSAIDs safety and toxicity.
Sujet(s)
Anti-inflammatoires non stéroïdiens/pharmacologie , Acide arachidonique/métabolisme , Cytochrome P-450 enzyme system/métabolisme , Inflammation/traitement médicamenteux , Inflammation/métabolisme , Animaux , Arthrite expérimentale/traitement médicamenteux , Arthrite expérimentale/métabolisme , Célécoxib/pharmacologie , Coeur/effets des médicaments et des substances chimiques , Acide hydroxyeïcosatétraénoïque/pharmacologie , Rein/effets des médicaments et des substances chimiques , Rein/métabolisme , Lactones/pharmacologie , Mâle , Méloxicam , Rats , Rat Sprague-Dawley , Sulfones/pharmacologie , Thiazines/pharmacologie , Thiazoles/pharmacologieRÉSUMÉ
A co-morbidity of inflammatory conditions is increased cardio-renal risks. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) which are used to treat pain and inflammation are also associated with increase in such risks. We hypothesized that inflammation and NSAIDs impose the cardio-renal risk through the activation of the renin-angiotensin-system (RAS), a regulating pathway of the renal and cardiovascular homeostasis. We investigated the effect of adjuvant arthritis and NSAIDs on the RAS. Western blotting and ELISA were used to measure the RAS components. Inflammation caused significant imbalances in the cardiac and renal angiotensin converting enzymes, their biologically active angiotensin peptides (AngII and Ang1-7) and the target proteins involved in the peptide-receptor binding (AngII type 1 and type 2, and Ang1-7 receptor, Mas) toward cardio-renal toxicity. However, 7 days treatment of arthritic animals with NSAIDs (rofecoxib, meloxicam, celecoxib and flurbiprofen) restored the constitutive balances, perhaps due to their anti-inflammatory properties. Inflammation exerts its cardio-renal effects by causing imbalance in the RAS. NSAIDs through their anti-inflammatory effect restore this imbalance. Thus, mechanisms other than imbalances in the RAS may be involved in the NSAIDs cardiotoxicity.
RÉSUMÉ
BACKGROUND: Both omeprazole and its S enantiomer (esomeprazole) have been available and used to treat symptoms of gastroesophageal reflux disease (GERD) and conditions associated with excessive stomach acid secretion for more than a decade. Controversy exists over improved efficacy of S enantiomer (esomeprazole) over parent racemate (omeprazole). However, a comparison of the clinical outcomes of these products may reveal the rationale for switching from the racemate to single enantiomer. Since enantiomers of omeprazole are equipotent, we compared the outcomes of equal doses of each product to see if both actually differ in their efficacy's or the reported superiority of S enantiomer is just a dose effect. METHODS: A web search was carried out for randomized controlled trials with head-to-head comparisons of omeprazole and S-omeprazole. The data were abstracted and after calculating the odd ratios (OR) for the outcomes reported in each study, the combined overall odd ratios (OR') were estimated. The random effect inverse variance method with omeprazole as the reference (OR" = 1) was used. RESULTS: Out of 1171 studies, 14 were deemed eligible. There was no significant difference in the therapeutic success between omeprazole and S-omeprazole as a part of triple therapy for the treatment of H. pylori in both intention-to-treat (OR', 1.06; CI, 0.83, 1.36; p = 0.63) as well as per-protocol analysis (OR', 1.07; CI, 0.84, 1.36; p = 0.57). For the treatment of gastro-oesophageal reflux disease, S-omeprazole was significantly but marginally superior to the racemate (OR', 1.18; CI, 1.01, 1.38; p = 0.04). The two products were equipotent in all metrics used to assess intragastric pH except for the % patients maintaining a 24 h gastric pH above 4 (1.57; CI, 1.04, 2.381; p = 0.03). CONCLUSION: The therapeutic benefit of chiral switch of omeprazole is questionable considering the substantially greater economic burden involved.
Sujet(s)
Ésoméprazole/usage thérapeutique , Oméprazole/usage thérapeutique , Inhibiteurs de la pompe à protons/usage thérapeutique , Reflux gastro-oesophagien/traitement médicamenteux , Infections à Helicobacter/traitement médicamenteux , Humains , Inhibiteurs de la pompe à protons/composition chimique , Essais contrôlés randomisés comme sujet , StéréoisomérieRÉSUMÉ
Synthetic analogues of the peptide hormone calcitonin have been used in medicine as biologic drug therapies for decades, to treat pathological conditions of excessive bone turnover, such as osteoporosis, where more bones are removed than replaced during bone remodeling. Osteoporosis and other chronic skeletal diseases, including inflammatory arthritis, exact a substantial and growing toll on aging populations worldwide however they respond poor to synthetic biologic drug therapy, due in part to the rapid half-life of elimination, which for calcitonin is 43 minutes. To address those shortcomings, we have developed and synthesized bone-targeting variants of calcitonin as a targeted drug delivery strategy, by conjugation to bisphosphonate drug bone-seeking functional groups in highly specific reaction conditions. To evaluate their in vivo efficacy, bisphosphonate-mediated bone targeting with PEGylated (polyethylene glycol conjugated) and non-PEGylated salmon calcitonin analogues were synthesized and dose escalation was performed in female rats developing Osteoporosis. The bone-targeting calcitonin analogues were also tested in a separate cohort of male rats developing adjuvant-induced arthritis. Ovariectomized female rats developing Osteoporosis were administered daily sub-cutaneous injection of analogues equivalent to 5, 10 and 20 IU/kg of calcitonin for 3 months. Adjuvant arthritis was developed in male rats by administering Mycobacterium butyricum through tail base injection. Daily sub-cutaneous injection of analogues equivalent to 20 IU/kg of calcitonin was administered and the rats were measured for visible signs of inflammation to a 21 day endpoint. In both studies, the effect of drug intervention upon bone volume and bone mineral density (BMD) was assessed by measuring the trabecular bone volume percentage and BMD at the proximal tibial metaphysis using in vivo micro-computed tomography. With dose escalation studies, only bone targeting analogue dosed groups showed a trend towards increased BMD and bone volume at 4, 8 and 12 weeks. Significant preservation of bone volume and BMD as evidenced by nonsignificant (P<0.05) loss of bone volume and BMD at the end of 3 month study endpoint was seen in animals dosed with 20 IU/kg of calcitonin compounds. Similarly, in case of adjuvant-induced arthritis rats, there was a significant increase (P<0.05) in bone volume and BMD in calcitonin-bisphosphonate and calcitonin-PEG-bisphosphonate treated groups at 21 days compared to the baseline values. Improved efficacy in terms of preserving bone volume and BMD in Osteoporosis, and in rats developing adjuvant-induced arthritis, by these analogues suggests their potential as new drug candidates for further evaluation to determine their usefulness in bone diseases characterized by excessive bone resorption.
Sujet(s)
Arthrite expérimentale/traitement médicamenteux , Agents de maintien de la densité osseuse/administration et posologie , Calcitonine/administration et posologie , Diphosphonates/administration et posologie , Ostéoporose post-ménopausique/traitement médicamenteux , Animaux , Articulation talocrurale/imagerie diagnostique , Articulation talocrurale/effets des médicaments et des substances chimiques , Articulation talocrurale/physiopathologie , Arthrite expérimentale/imagerie diagnostique , Arthrite expérimentale/microbiologie , Arthrite expérimentale/physiopathologie , Densité osseuse/effets des médicaments et des substances chimiques , Agents de maintien de la densité osseuse/composition chimique , Remodelage osseux/effets des médicaments et des substances chimiques , Calcitonine/composition chimique , Chimie pharmaceutique , Diphosphonates/composition chimique , Vecteurs de médicaments , Femelle , Humains , Injections sous-cutanées , Mâle , Mycobacterium , Ostéoporose post-ménopausique/imagerie diagnostique , Ostéoporose post-ménopausique/étiologie , Ostéoporose post-ménopausique/physiopathologie , Ovariectomie , Polyéthylène glycols/composition chimique , Rat Sprague-Dawley , Technologie pharmaceutique/méthodes , Tibia/imagerie diagnostique , Tibia/effets des médicaments et des substances chimiques , Tibia/physiopathologie , Facteurs temps , Microtomographie aux rayons XRÉSUMÉ
Eicosanoids are biologically active lipid-derived oxidative metabolites of arachidonic acid. We, herein, present an improved sensitive, selective and robust high performance liquid chromatography (HPLC)-fluorescence assay for simultaneous quantification of eicosanoids in human plasma and rat tissues. Aliquots of 200 µL of plasma or 30 mg of heart or kidney tissues were spiked with 16-hydroxydecanoic acid as internal standard, and extracted with anhydrous acetonitrile using solid phase cartridges. The eluted samples were dried, reconstituted in anhydrous acetonitrile and labeled with 2-(2,3-naphthalimino)ethyl-trifluoromethanesulphonate in the presence of saturated potassium fluoride solution in anhydrous acetonitrile and N,N-diiospropylethylamine as catalyst. The derivatized eicosanoids were extracted with anhydrous acetonitrile using solid phase cartridges. Chromatographic separation was achieved on a C18 reversed phase column using gradient mobile phase of 0.05% of formic acid:acetonitrile:water at 0.8 mL/min flow rate. The analytes were detected at excitation and emission wavelength of 260 and 396 nm, respectively. The assay was linear (r(2)≥ 0.98) in the concentration range of 0.01-2.5 µg/mL. The intra-day and inter-day coefficients variation was less than 19.8%. Using this assay, we were able to quantify arachidonic acid metabolites simultaneously in human and rat biological samples.
Sujet(s)
Acides arachidoniques/sang , Chromatographie en phase liquide à haute performance , Chromatographie en phase inverse , Rein/composition chimique , Myocarde/composition chimique , Spectrométrie de fluorescence , Animaux , Calibrage , Chromatographie en phase liquide à haute performance/normes , Chromatographie en phase inverse/normes , Humains , Limite de détection , Modèles linéaires , Mâle , Rat Sprague-Dawley , Normes de référence , Reproductibilité des résultats , Spectrométrie de fluorescence/normesRÉSUMÉ
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are known to increase the risk of cardiovascular (CV) and renal incidences, especially at higher doses and upon long term use. However, the available reports are criticized for lack of specificity, grouping of vastly different outcomes together and ignoring the heterogeneity among NSAIDs. In this systematic review, we are reporting CV/renal risks associated with meloxicam, stratified into myocardial, vascular, renal risk categories, to address the differential nature of NSAIDs effects on different body systems. We are also reporting composite CV/renal risk to present overall risk associated with various covariates. METHODS: We searched the online healthcare databases for observational studies or randomized controlled trials, reporting myocardial or all-cause mortality outcome (>90 days exposure) and/or vascular/renal outcomes (any exposure) after meloxicam use, published until April 2014. The combined odd ratio values (OR'; 95% CI) were calculated using the random effect inverse variance model. RESULTS: We found 19 eligible studies out of 2,422 reports. Meloxicam demonstrated a low increase in composite risk (OR' 1.14; CI 1.04-1.25) which was mainly vascular in nature (OR' 1.35; CI 1.18-1.55] as it did not elevate myocardial (OR' 1.13; CI 0.98-1.32) or renal (OR', 0.99; CI 0.72-1.35) risks. Relative to meloxicam, other NSAIDs increased the composite risk, in a dose-dependent fashion, in the following order: rofecoxib > indomethacin > diclofenac > celecoxib > naproxen > ibuprofen. OR' was also influenced by type of disease and the comparator used, and acetylsalicylic acid. CONCLUSION: NSAIDs are heterogeneous in increasing CV/renal risks. The low increased risk associated with meloxicam is mainly vascular in origin.
Sujet(s)
Anti-inflammatoires non stéroïdiens/effets indésirables , Maladies cardiovasculaires/induit chimiquement , Inhibiteurs de la cyclooxygénase 2/effets indésirables , Maladies du rein/induit chimiquement , Thiazines/effets indésirables , Thiazoles/effets indésirables , Maladies vasculaires/induit chimiquement , Animaux , Maladies cardiovasculaires/diagnostic , Maladies cardiovasculaires/épidémiologie , Études cas-témoins , Humains , Maladies du rein/diagnostic , Maladies du rein/épidémiologie , Méloxicam , Essais contrôlés randomisés comme sujet/méthodes , Facteurs de risque , Maladies vasculaires/diagnostic , Maladies vasculaires/épidémiologieRÉSUMÉ
There is a debate on the dose dependency, concentration-effect, hence, the beneficial effect of glucosamine (GlcN), a widely used anti-inflammatory natural product. We investigated dose/concentration-effect relationship and determined its minimum effective dose/concentration in rats with adjuvant arthritis (AA, Mycobacterium butyricum in squalene) both as preventive and ameliorating interventions. To control already emerged arthritis, rats received oral doses of placebo or 160 mg/kg.day(-1) GlcN for 6 days. For prevention, rats were orally administered 0, 20, 40, 80, or 160 mg/kg.day(-1) GlcN commencing on the day of adjuvant injection. The arthritis index (AI), serum nitrite, and body weight were recorded. Subsequently, animals were cannulated in the right jugular veins and blood samples were collected for the determination of GlcN. GlcN ameliorated and, dose-dependently, prevented AA. It also controlled nitrite. AI was inversely correlated with GlcN dose, maximum plasma concentration, and the area under the concentration curve. Minimum effective dose was approximately 40 mg/kg.day(-1) that correspond to maximum plasma concentration of 1.37 ± 0.24 mg/L, close to 1.6 mg/L reported for pharmaceutical grades of GlcN to humans. GlcN efficacy is dose and concentration dependent. If the data extrapolated to humans, a higher than the commonly tested 1500 mg/kg dosage regimen may provide more clear treatment outcomes.
Sujet(s)
Anti-inflammatoires/administration et posologie , Anti-inflammatoires/pharmacocinétique , Arthrite expérimentale/traitement médicamenteux , Glucosamine/administration et posologie , Glucosamine/pharmacocinétique , Analyse de variance , Animaux , Anti-inflammatoires/usage thérapeutique , Aire sous la courbe , Arthrite expérimentale/anatomopathologie , Chromatographie en phase liquide à haute performance , Cytokines/métabolisme , Relation dose-effet des médicaments , Glucosamine/usage thérapeutique , Interleukine-1 bêta/métabolisme , Interleukine-6/métabolisme , Articulations/anatomopathologie , Mâle , Nitrites/sang , Rats , Rat Sprague-Dawley , Facteur de nécrose tumorale alpha/métabolisme , Prise de poids/effets des médicaments et des substances chimiquesRÉSUMÉ
Non-steroidal anti-inflammatory drugs (NSAIDs) are used chronically to reduce pain and inflammation in patients with arthritic conditions, and also acutely as analgesics by many patients. Both therapeutic and adverse effects of NSAIDs are due to inhibition of cyclooxygenase (COX) enzyme. NSAIDs are classified as non-selective and COX-2-selective inhibitors (COXIBS) based on their extent of selectivity for COX inhibition. However, regardless of their COX selectivity, reports are still appearing on the GI side effect of NSAIDs particularly on the lower gastrointestinal (GI) tract and the harmful role of their controlled release formulations. In addition, previously unpublished data stored in the sponsor's files, question the GI sparing properties of rofecoxib, a COXIB that has been withdrawn due to cardiovascular (CV) side effects. Presently, the major side effects of NSAIDs are the GI complications, renal disturbances and CV events. There is a tendency to believe that all NSAIDs are associated with renal and CV side effects, a belief that is not supported by solid evidence. Indeed, lower but still therapeutics doses of some NSAIDs may be cardioprotective. In this review, we briefly discuss the GI toxicity of the NSAIDs and assess their renal and CV adverse effects in more detail.